D036104Chemicals & DrugsD08.811.913.696.620.682.725.400.850.100D12.776.543.750.630.500.100Receptor, EphA2prns:hasAuthorListauthor listprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfConnectionsnumber of connectionsprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierInformation Resourcevivo:subjectAreaForsubject area forrdf:predicatepredicaterdf:typetyperdfs:labellabelConcept0.4306740.3994952subject area for22228563Tandon M, Vemula SV, Sharma A, Ahi YS, Mittal S, Bangari DS, Mittal SKThe journal of gene medicineEphrinA1-EphA2 interaction-mediated apoptosis and FMS-like tyrosine kinase 3 receptor ligand-induced immunotherapy inhibit tumor growth in a breast cancer mouse model. J Gene Med. 2012 Feb; 14(2):77-89.J Gene Med2012-02-01T00:00:002012EphrinA1-EphA2 interaction-mediated apoptosis and FMS-like tyrosine kinase 3 receptor ligand-induced immunotherapy inhibit tumor growth in a breast cancer mouse model.21142802Tandon M, Vemula SV, Mittal SKExpert opinion on therapeutic targetsEmerging strategies for EphA2 receptor targeting for cancer therapeutics. Expert Opin Ther Targets. 2011 Jan; 15(1):31-51.Expert Opin Ther Targets2011-01-01T00:00:002011Emerging strategies for EphA2 receptor targeting for cancer therapeutics.